Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study)
Sponsor: VA Office of Research and Development
Summary
The purpose of this study is to test the drug CORT108297, which blocks the hormone cortisol, for treatment of PTSD in Veterans, and establish a safety profile that will inform the design of future studies.
Official title: Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD)
Key Details
Gender
All
Age Range
18 Years - 69 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2022-10-15
Completion Date
2026-12-31
Last Updated
2026-01-29
Healthy Volunteers
No
Conditions
Interventions
CORT108297
CORT108297- 180mg daily for 7 days
Placebo
Placebo- 180mg daily for 7 days
Locations (2)
Tuscaloosa VA Medical Center, Tuscaloosa, AL
Tuscaloosa, Alabama, United States
San Francisco VA Medical Center, San Francisco, CA
San Francisco, California, United States